

Role of PKGI α -mediated Spinal Dorsal Horn Plasticity in Chronic Pain

Sufang Liu^{1,2}, Changsheng Li^{1,2}, Ying Xing^{2,3} and Feng Tao^{1*}

¹Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

²Basic Medical College, Zhengzhou University, Zhengzhou, Henan, China

³Basic Medical College, Xinxiang Medical University, Xinxiang, Henan, China

Chronic pain due to a variety of health conditions is the primary reason people seek medical care, yet current therapies either are inadequate or cause intolerable side effects. Understanding cellular and molecular processes that lead to the initiation and maintenance of chronic pain will give promise to the development of more effective, more specific pain therapies. Chronic pain is an expression of neuronal plasticity, which is mediated in part by increased excitability of nociceptive neurons in the dorsal horn of the spinal cord [1]. The molecular mechanisms that underlie this nociceptive plasticity are not fully understood. In the spinal cord, Nitric Oxide (NO) is known to contribute to central mechanisms that induce hyperalgesia and allodynia [2-9]. There is also convincing evidence that a downstream molecule of the NO-cyclic guanosine monophosphate (cGMP) signaling pathway, Protein Kinase G (PKG), is involved in spinal nociceptive processing [10-16]. However, PKG phosphorylation targets in the spinal cord and their role in the central sensitization of chronic pain have not been elucidated.

Previous studies have focused on understanding the role of the NO synthases (NOS), soluble guanylyl cyclase (sGC) and PKG that participate in the NO-cGMP-PKG signaling pathway in chronic pain. Each of these proteins is up regulated in chronic pain, and blockade of any of these steps results in a profound reduction in the development of chronic pain. Endogenous NO is produced by NOS, of which neuronal NOS (nNOS) is activated and up-regulated after *N*-Methyl-D-Aspartate (NMDA) receptor stimulation in the central nervous system (CNS) [17-20]. It is widely accepted that NO is an important mediator in spinal nociceptive processing and contributes to molecular mechanisms of hyperalgesia and allodynia. The NO signal is transduced through the activation of the sGC, elevated cGMP levels and activation of the cGMP-dependent PKG, which is an intracellular target for cGMP. PKG has two isoenzymes in mammals, cytosolic PKGI and membrane-bound PKGII. Furthermore, PKGI has been shown to exist in two isoforms, PKGI α and PKGI β [21,22]. PKGII is not found in the spinal cord [16]. The NO-cGMP-PKG signaling pathway has become increasingly important as our understanding of its diverse biological actions has expanded, especially within the CNS [8,23,24]. Considerable evidence has demonstrated that the NO-cGMP-PKG signaling pathway is present in the neurons of the spinal cord and contributes to the development of hyperalgesia and allodynia in models of acute and chronic pain [8,11,12,14,16]. We have found that PKGI α is abundantly expressed in the superficial laminae at different spinal cord levels and is upregulated by intraplantar injection of complete Freund's adjuvant in the spinal cord. Noxious stimulation increases NOS expression [25-27], cGMP content [28], and PKGI α expression [12,16] in the spinal cord. Administration of inhibitors of NOS, sGC, and PKGI causes analgesic effects [3,4,9,11,12, 16,20,29-31] and enhances antinociception mediated by opioid receptors [32-34]. In addition, reduced formalin-evoked nociception and inflammatory hyperalgesia are observed in PKGI-deficient mice [14]. These studies provide strong evidence that the NO-cGMP-PKG signaling pathway plays an important role in pain modulation.

Chronic pain, consisting of tissue damage-induced inflammatory pain and nerve injury-induced neuropathic pain, is an expression of neuronal plasticity. One component of the plasticity is that the afferent input generated by injury and intense noxious stimuli triggers an

increased excitability of nociceptive neurons in the spinal cord. This central sensitization is an activity-dependent functional plasticity that results from activation of different intracellular kinase cascades leading to the phosphorylation of key membrane receptors and channels, increasing synaptic efficacy [1]. The NO-cGMP-PKG signaling pathway is required for noxious stimulation-produced transcription-dependent, long-term sensitization of nociceptive sensory neurons [35]. For example, in nociceptive neurons of *Aplysia*, PKGI is located in axons, where it is activated by nerve injury. In the activated state, PKGI is transported retrogradely to the cell body and phosphorylates a Mitogen-Activated Protein Kinase (MAPK). This phosphorylation triggers MAPK translocation into the nucleus and subsequent alterations in gene expression [36].

Protein phosphorylation is a notable post-translational modulation in nociceptive neurons [1]. Pain hypersensitivity is the consequence of early post-translational changes, both in the peripheral terminals of the nociceptor and in the spinal dorsal horn neurons. This neuroplasticity is the consequence of a combination of activity-dependent changes in the neurons and specific signal molecules initiating particular signal-transduction pathways. These pathways phosphorylate membrane proteins, changing their function, and activate transcription factors, altering gene expression [37]. PKG is a serine-threonine kinase, and it functions mainly by targeting its substrates and phosphorylating the targeted molecules at serine and/or threonine residues. The phosphorylation of these molecules will result in a series of physiological responses. A few molecules have been reported to be involved in the PKG signaling pathway as its phosphorylation targets and might play important roles in spinal PKGI α -mediated central sensitization of chronic pain. For instance, the family of Transient Receptor Potential Channels (TRPCs) is the vanguard of sensory systems, responding to temperature, touch, pain, osmolarity, pheromones, taste and other stimuli [38,39]. PKG can phosphorylate TRPC3 at Thr-11 and Ser-263, causing inactivation of TRPC3 [40]. In contrast, Ca²⁺ influx triggered by the activation of TRPCs contributes to the production of NO, which subsequently stimulates the NO-cGMP-PKG signaling pathway [41].

In conclusion, PKGI α might be involved in spinal nociceptive processing by phosphorylating its target proteins and thereby mediating spinal dorsal horn plasticity in chronic pain.

References

1. Ji RR, Woolf CJ (2001) Neuronal plasticity and signal transduction in nociceptive

*Corresponding author: Feng Tao, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA, Tel: 410-614-8059; Fax: 410-614-7711; E-mail: ftao81@jhmi.edu

Received January 15, 2014; Accepted February 13, 2014; Published February 15, 2014

Citation: Liu S, Li C, Xing Y, Tao F (2014) Role of PKGI α -mediated Spinal Dorsal Horn Plasticity in Chronic Pain. J Pain Relief 3: 134. doi:10.4172/2167-0846.1000134

Copyright: © 2014 Liu S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

- neurons: implications for the initiation and maintenance of pathological pain. *Neurobiol Dis* 8: 1-10.
2. Xu L, Mabuchi T, Katano T, Matsumura S, Okuda-Ashitaka E, et al. (2007) Nitric oxide (NO) serves as a retrograde messenger to activate neuronal NO synthase in the spinal cord via NMDA receptors. *Nitric Oxide* 17: 18-24.
 3. Tao F, Tao YX, Zhao C, Doré S, Liaw WJ, et al. (2004) Differential roles of neuronal and endothelial nitric oxide synthases during carrageenan-induced inflammatory hyperalgesia. *Neuroscience* 128: 421-430.
 4. Chu YC, Guan Y, Skinner J, Raja SN, Johns RA, et al. (2005) Effect of genetic knockout or pharmacologic inhibition of neuronal nitric oxide synthase on complete Freund's adjuvant-induced persistent pain. *Pain* 119: 113-123.
 5. Hoheisel U, Mense S (2000) The role of spinal nitric oxide in the control of spontaneous pain following nociceptive input. *Prog Brain Res* 129: 163-172.
 6. Osborne MG,Coderre TJ (1999) Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. *Br J Pharmacol* 126: 1840-1846.
 7. Meller ST, Cummings CP, Traub RJ, Gebhart GF (1994) The role of nitric oxide in the development and maintenance of the hyperalgesia produced by intraplantar injection of carrageenan in the rat. *Neuroscience* 60: 367-374.
 8. Meller ST, Gebhart GF (1993) Nitric oxide (NO) and nociceptive processing in the spinal cord. *Pain* 52: 127-136.
 9. Malmberg AB, Yaksh TL (1993) Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. *Pain* 54: 291-300.
 10. Patil CS, Padi SV, Singh VP, Kulkarni SK (2006) Sildenafil induces hyperalgesia via activation of the NO-cGMP pathway in the rat neuropathic pain model. *Inflammopharmacology* 14: 22-27.
 11. Tao YX, Johns RA (2000) Activation of cGMP-dependent protein kinase α is required for N-methyl-D-aspartate- or nitric oxide-produced spinal thermal hyperalgesia. *Eur J Pharmacol* 392: 141-145.
 12. Tao YX, Hassan A, Haddad E, Johns RA (2000) Expression and action of cyclic GMP-dependent protein kinase α in inflammatory hyperalgesia in rat spinal cord. *Neuroscience* 95: 525-533.
 13. Tegeder I, Schmidtko A, Niederberger E, Ruth P, Geisslinger G (2002) Dual effects of spinally delivered 8-bromo-cyclic guanosine mono-phosphate (8-bromo-cGMP) in formalin-induced nociception in rats. *Neurosci Lett* 332: 146-150.
 14. Tegeder I, Del Turco D, Schmidtko A, Sausbier M, Feil R, et al. (2004) Reduced inflammatory hyperalgesia with preservation of acute thermal nociception in mice lacking cGMP-dependent protein kinase I. *Proc Natl Acad Sci U S A* 101: 3253-3257.
 15. Mixcoatl-Zecuatl T, Flores-Murrieta FJ, Granados-Soto V (2006) The nitric oxide-cyclic GMP-protein kinase G-K⁺ channel pathway participates in the antialloodynic effect of spinal gabapentin. *Eur J Pharmacol* 531: 87-95.
 16. Schmidtko, A., Ruth, P., Geisslinger, G., & Tegeder, I (2003) Inhibition of cyclic guanosine 5'-monophosphate-dependent protein kinase I (PKG-I) in lumbar spinal cord reduces formalin-induced hyperalgesia and PKG upregulation. *Nitric Oxide* 8, 89-94
 17. Ayata C, Ayata G, Hara H, Matthews RT, Beal MF, et al. (1997) Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. *J Neurosci* 17: 6908-6917.
 18. Maihofner, C (2000) Regulation and immunohistochemical localization of nitric oxide synthases and soluble guanylyl cyclase in mouse spinal cord following nociceptive stimulation. *Neurosci. Lett.* 290, 71-75
 19. Kawamata, T. & Omote, K (1999) Activation of spinal N-methyl-D-aspartate receptors stimulates a nitric oxide/cyclic guanosine 3,5-monophosphate/glutamate release cascade in nociceptive signaling. *Anesthesiology* 91, 1415-1424.
 20. Meller ST, Dykstra C, Gebhart GF (1992) Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-D-aspartate-produced facilitation of the nociceptive tail-flick reflex. *Eur J Pharmacol* 214: 93-96.
 21. Lincoln TM, Cornwell TL (1993) Intracellular cyclic GMP receptor proteins. *FASEB J* 7: 328-338.
 22. Wang X, Robinson PJ (1997) Cyclic GMP-dependent protein kinase and cellular signaling in the nervous system. *J Neurochem* 68: 443-456.
 23. Bredt DS, Hwang PM, Snyder SH (1990) Localization of nitric oxide synthase indicating a neural role for nitric oxide. *Nature* 347: 768-770.
 24. Snyder SH (1992) Nitric oxide: first in a new class of neurotransmitters. *Science* 257: 494-496.
 25. Herdegen T, Rüdiger S, Mayer B, Bravo R, Zimmermann M (1994) Expression of nitric oxide synthase and colocalisation with Jun, Fos and Krox transcription factors in spinal cord neurons following noxious stimulation of the rat hindpaw. *Brain Res Mol Brain Res* 22: 245-258.
 26. Lam HH, Hanley DF, Trapp BD, Saito S, Raja S, et al. (1996) Induction of spinal cord neuronal nitric oxide synthase (NOS) after formalin injection in the rat hind paw. *Neurosci Lett* 210: 201-204.
 27. Wu J, Lin Q, Lu Y, Willis WD, Westlund KN (1998) Changes in nitric oxide synthase isoforms in the spinal cord of rat following induction of chronic arthritis. *Exp Brain Res* 118: 457-465.
 28. Garry MG, Richardson JD, Hargreaves KM (1994) Carrageenan-induced inflammation alters the content of i-cGMP and i-cAMP in the dorsal horn of the spinal cord. *Brain Res* 646: 135-139.
 29. Haley JE, Sullivan AF, Dickenson AH (1990) Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat. *Brain Res* 518: 218-226.
 30. Meller ST, Pechman PS, Gebhart GF, Maves TJ (1992) Nitric oxide mediates the thermal hyperalgesia produced in a model of neuropathic pain in the rat. *Neuroscience* 50: 7-10.
 31. Moore PK, Oluoyomi AO, Babbedge RC, Wallace P, Hart SL (1991) L-NG-nitro arginine methyl ester exhibits antinociceptive activity in the mouse. *Br J Pharmacol* 102: 198-202.
 32. Machelska H, Labuz D, PrzewÅ,ocki R, PrzewÅ,ocka B (1997) Inhibition of nitric oxide synthase enhances antinociception mediated by μ , δ and κ opioid receptors in acute and prolonged pain in the rat spinal cord. *J Pharmacol Exp Ther* 282: 977-984.
 33. Xu JY, Tseng LF (1995) Nitric oxide/cyclic guanosine monophosphate system in the spinal cord differentially modulates intracerebroventricularly administered morphine- and beta-endorphin-induced antinociception in the mouse. *J. Pharmacol. Exp. Ther.* 274, 8-16
 34. Xu JY, Hill KP, Bidlack JM (1998) The nitric oxide/cyclic GMP system at the supraspinal site is involved in the development of acute morphine antinociceptive tolerance. *J Pharmacol Exp Ther* 284: 196-201.
 35. Lewin MR, Walters ET (1999) Cyclic GMP pathway is critical for inducing long-term sensitization of nociceptive sensory neurons. *Nat Neurosci* 2: 18-23.
 36. Sung YJ, Walters ET, Ambron RT (2004) A neuronal isoform of protein kinase G couples mitogen-activated protein kinase nuclear import to axotomy-induced long-term hyperexcitability in Aplysia sensory neurons. *J Neurosci* 24: 7583-7595.
 37. Woolf CJ, Costigan M (1999) Transcriptional and posttranslational plasticity and the generation of inflammatory pain. *Proc Natl Acad Sci U S A* 96: 7723-7730.
 38. Minke B (2006) TRP channels and Ca²⁺ signaling. *Cell Calcium* 40: 261-275.
 39. Clapham DE (2003) TRP channels as cellular sensors. *Nature* 426: 517-524.
 40. Yao X (2007) TRPC, cGMP-dependent protein kinases and cytosolic Ca²⁺. *Handb Exp Pharmacol* : 527-540.
 41. Brito GA, Sachs D, Cunha FQ, Vale ML, Lotufo CM, et al. (2006) Peripheral antinociceptive effect of pertussis toxin: activation of the arginine/NO/cGMP/PKG/ATP-sensitive K channel pathway. *Eur J Neurosci* 24: 1175-1181.